Nasal spray COVID vaccine shows promise in new trial

NCT ID NCT05736835

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new COVID-19 vaccine given as a nasal spray. It aims to see if the spray is safe and helps the body fight the virus. About 227 healthy adults aged 18 to 80 will take part. The vaccine is designed to boost immunity in the nose, where the virus often enters.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229, United States

  • University of Rochester

    Rochester, New York, 14642, United States

  • Velocity Clinical Research

    San Diego, California, 91942, United States

  • Velocity Clinical Research

    Boise, Idaho, 83642, United States

  • Velocity Clinical Research

    Sioux City, Iowa, 51106, United States

  • Velocity Clinical Research

    Rockville, Maryland, 20854, United States

  • Velocity Clinical Research

    Omaha, Nebraska, 68134, United States

  • Velocity Clinical Research

    Vestal, New York, 13850, United States

  • Velocity Clinical Research

    Providence, Rhode Island, 02818, United States

  • Velocity Clinical Research

    Cedar Park, Texas, 78759, United States